Russian Federation: Tightening Control Over Prices For Crucial Medicines

Last Updated: 24 June 2015
Article by Anna McDonald

Governmental regulation of vital and essential medicines (hereinafter Essential Drugs) in the Russian Federation in the form in which it exists today has been functioning since 2010. The list of Essential Drugs (“EDL List”) has already been updated several times but the essence of regulation remains the same.

Subject to restriction is the maximum price for EDL Drugs. This price must be calculated by determining (and registering) the manufacturer's sales price and applying wholesale and retail markups that are set by the Russian Federation constituent entities. Dealing in EDL durgs imposes additional obligations on all participants in the distribution chain from the manufacturer to the retail seller, starting with compliance with the pricing procedure and ending with the need to prepare additional documentation such as, for example, a price negotiation protocol.

The local divisions of a number of state authorities may audit a retail seller's compliance with pricing rules for EDL drugs:

  • the Federal Healthcare Supervisory Service ("Roszdravnadzor");
  • the Prosecutor's Office;
  • the Federal Antimonopoly Service ("FAS") (if the audit is of a dominant entity or otherwise related to the antimonopoly legislation);
  • other competent authorities of the RF constituent entity, such as various tariff and pricing policy committees, consumer social protection departments, etc.

Liability for overcharging for EDL drugs arises under Article 14.6 (Violation of Pricing Procedure) of the Russian Federation Code on Administrative Offenses (for legal entities the penalty is double the extra proceeds from the sale of an EDL drug over the registered  prices for such EDL drug for the entire period during which the offense was committed, but not more than one year).

Since its introduction, regional regulation of EDL drugs has led to differences in the degree and measures for exercising control in various constituent entities of the Russian Federation. Audits may be conducted both during general audits of compliance with the law and licensing requirements, as well as in response to consumer complaints. Individual audits at a specific entity or at a specific pharmacy are interspersed with mass audits. For example, recently the Prosecutor's Office initiated mass audits of retail prices for EDL drugs in Moscow.[1]

Prices for many pharmaceuticals (including EDL drugs) started to actively go up at the end of 2014 with the fall of the ruble exchange rate. This led to a growing number of complaints both from end consumers and from wholesale distributors. The number of audits also increased. For example, as early as February 26, 2015 the FAS sent an order calling to tighten control over pricing of dominant entities at the regional retail markets for pharmaceuticals, medical devices and associated goods. According to the comments of their representatives, many FAS departments [2] renewed monitoring of prices for EDL drugs. In April 2015 the General Prosecutor's Office and the FAS received an appeal from the Audit Chamber calling on them to check into the rise in medicine prices.

The numerous audits yielded results. As at the end of April 2015 the Prosecutor's Office had opened 779 administrative offense cases in 2015 for exceeding the permitted markups on EDL drugs [3].  On May 18, 2015 the FAS published information [4] that, according to the results of audits, 14 administrative investigations were initiated in a number of constituent entities based upon the evidence of overstated prices of EDL drugs. Regional regulation is also getting tighter. For example, Moscow Government Resolution No. 134-PP of March 24, 2015 gave the Moscow Department of Health the right to initiate and resolve administrative offense cases related to pricing of EDL drugs (prior to that time the Health Department had the authority to conduct audits and issue directives, but was not entitled to initiate the relevant cases on its own).

RF Government Decree No. 434 "On Regional State Control over the Application of Prices for Medicines on the List of Crucial Medicines" (the Decree) was enacted on May 6, 2015. According to the Decree, the relevant competent executive authorities of Russian Federation constituent entities (primarily the Roszdravnadzor authorities) monitor prices of EDL drugs by:

  • organizing and conducting audits of the monitored entity's compliance with mandatory requirements;
  • systematically observing the performance of mandatory requirements by a monitored entity; taking steps, according to the procedure of Russian Federation law, to stop discovered violations of
  • mandatory requirements and/or remedy the consequences of such violations, issue directives to remedy discovered violations of mandatory requirements and take steps to prosecute the offenders.

Comments of experts and representatives of Roszdravnadzor on the Decree differ. For example, adviser to the head of Roszdravnadzor Olga Maleeva asserts that [5] the Decree merely specifies powers that already belonged to the regional authorities. Other specialists and representatives of Roszdravnadzor assert that the Resolution formally establishes the right to conduct audits that are specifically oriented toward pricing of EDL drugs.

Amendments are already being made to regional acts to reflect in them the principles stipulated in the Decree. For example, the Administrative Regulations for the Moscow Department of Health to perform the state function of regional state control over the application of prices of medicines on the EDL list (approved by the Moscow Government Resolution of November 18, 2014) have amended the previous Moscow City Government Resolution No. 320-PP of June 4, 2015. For one thing, a new method of controlling prices for EDL Drugs has been set up: systematic observation that does not require interaction with the entities being monitored. Observation is by "visual review" of information on the pharmaceutical entity's website. This is done at least once a month and the results are taken into consideration when the audit plans are being drawn up.  The authorities are not permitted to request any documents or information from pharmaceutical entities when performing such systematic observation.

Active audits of prices for EDL drugs—primarily retail prices—are expected to continue.


[2] / 

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
25 Oct 2018, Other, Munich, Germany

Please register via RSVP button by October 15, 2018. If you have any questions, please contact Marcel Schmidt.

30 Oct 2018, Other, Frankfurt, Germany

With the blockchain market maturing, we see an advancing diversification of token types and offerings.

30 Oct 2018, Other, London, UK

The third campaign in Dentons' TechTalk series explores the role of Blockchain in the modern business world.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions